Mounjaro®
Starting from £179.99/mo
Start journey Learn moreLeg pain is not listed among Mounjaro's common side effects in its UK prescribing information, but it does come up as a patient question. Here is the honest picture: tirzepatide's documented side effects are mostly gastrointestinal, yet some people on treatment do report musculoskeletal discomfort, and there are plausible reasons why. Whether your leg pain needs urgent attention or a quiet conversation with your prescriber depends on a few specific factors — and that is exactly what this page works through. Mounjaro (tirzepatide) is a prescription-only medicine; any new or worsening symptom during treatment should be discussed with a clinician who knows your full history.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The UK Summary of Product Characteristics for tirzepatide sets out side effects that appeared more often in trial participants than in those taking a placebo. The familiar ones are gastrointestinal: nausea, diarrhoea, vomiting, constipation and indigestion dominate. Injection-site reactions, fatigue, headache and dizziness also appear. Leg pain, as a standalone term, is not among them.
That absence matters but does not mean leg pain is impossible. Clinical trials capture effects that occur at statistically meaningful rates; rarer or coincidental events in a population do not always meet that threshold. The SURMOUNT-1 trial, which ran for 72 weeks across thousands of adults, was powered to detect common adverse events, it was not designed to rule out every individual symptom. So the prescribing information is not a complete list of everything anyone will ever feel; it is a list of what the evidence robustly attributes to the medicine itself.
A common assumption worth letting go gently: that if something happens while you are on a medicine, the medicine caused it. Sometimes leg pain during Mounjaro treatment is coincidental, a pulled muscle, a long walk, a night on an unfamiliar mattress. The timing does not prove the connection. What matters is the character of the pain, how quickly it came on and whether anything else is happening alongside it. The full Mounjaro overview on the nume site covers the broader side-effect picture if you want context on the medicine as a whole.
Even if tirzepatide is not directly causing leg pain through its pharmacology, treatment creates conditions that might contribute. The most credible indirect route is rapid early weight reduction. Losing a meaningful amount of body weight relatively quickly changes the mechanical load on the hips, knees and ankles. Joints that adapted to carrying a certain weight may respond to that shift with temporary soreness, particularly if activity levels increase at the same time, which many people on treatment find they have the energy to do, and understanding the full benefits of Mounjaro can help put those physical changes in context.
Muscle cramping is a related possibility. Some patients reduce their food intake considerably during the early weeks of treatment, and if that reduction affects electrolyte intake (particularly potassium, magnesium and calcium) cramping in the legs can follow. Dehydration compounds this, and nausea-driven reduced fluid intake is common early on. None of this is a pharmacological action of tirzepatide; it is a downstream effect of eating and drinking less. Staying well hydrated and keeping protein and micronutrient intake adequate matters throughout treatment, and your prescriber or a dietitian can advise on practical ways to do that.
For a closer look at the specific pattern of leg-related symptoms people report, the detailed page on Mounjaro and leg pain goes further into the clinical and patient-reported picture. There is also a separate look at whether Mounjaro can cause back pain, which follows a similar chain of reasoning about musculoskeletal load.
Most leg discomfort during treatment is benign and self-limiting. Some is not. The symptoms below are the ones that change the calculation and should prompt same-day or emergency medical contact rather than waiting for a routine check.
Sudden, severe leg pain combined with swelling, warmth or redness in the calf (especially if one leg is noticeably more affected than the other) can indicate a deep vein thrombosis. This is not a known effect of tirzepatide specifically, but it is a medical emergency if present, and obesity itself is a known risk factor for clotting. Do not drive yourself to hospital if you suspect this; call 999 or 111 depending on severity.
Leg pain with breathlessness, chest pain or a rapid heart rate could indicate a clot that has moved to the lung. Again: emergency services.
Severe pain in the thigh or hip after a fall, or pain that makes weight-bearing impossible, needs in-person assessment. Rapid weight change and altered gait can (rarely) increase fall risk, particularly early in treatment when energy levels fluctuate.
The MHRA's Yellow Card reporting scheme exists precisely for symptoms that patients and clinicians are uncertain about. If you experience something unexpected during treatment and want to flag it formally, that is the route. Reports help regulators build a more complete picture over time. The NHS also provides patient-facing information on tirzepatide covering what to watch for and when to seek help.
The practical question for most people reading this is whether their leg pain is a reason to stop, wait or simply mention it at the next review. The answer depends on what the prescriber hears when you describe it: onset, location, severity, what makes it better or worse and what else has changed. That conversation is the decision point, not this page.
At nume, a real clinician reads every consultation and review, your case goes to a GPhC-registered prescriber, not through an automated filter. If you are already a patient and something has changed, the aftercare team is available seven days a week via the contact page. If you are considering treatment and want to understand whether your specific health history changes the risk picture, a free consultation with our prescribers is the starting point: check your eligibility here.
For anyone curious about how tirzepatide works at a physiological level (which sometimes helps make sense of why certain symptoms do or do not appear) the tirzepatide overview covers the dual GIP and GLP-1 mechanism in plain terms. And if you are weighing up what treatment might look like practically, the weight-loss treatments page lays out the broader landscape. The cost of treatment is a practical consideration too; the information on getting Mounjaro through a regulated UK pharmacy covers what legitimate supply actually involves.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.